Research site

Katholisches Klinikum Koblenz Montabaur gGmbH

Germany Rudolf-Virchow-Strasse 7, Rauental, 56073 Koblenz, Germany

3 trials recruiting
Non-small cell lung cancer · Non-small cell lung cancer stage III · Non-small cell lung cancer stage IIIA
Adult patients

About Specializations

Katholisches Klinikum Koblenz Montabaur gGmbH in Koblenz, Germany specialises in clinical trials of conditions such as Non-small cell lung cancer, Non-small cell lung cancer stage III, Non-small cell lung cancer stage IIIA, Non-small cell lung cancer stage IIIB, and other specialisations. This site conducts important research.

Main research areas of the site

Oncology

The department concentrates on Neoplasms, with a primary focus on Metastatic Non-small Cell Lung Cancer and the investigation of Neoadjuvant/Adjuvant treatment for resectable stage II‑IIIA/B disease.

Evaluation of pembrolizumab combined with sacituzumab govitecan to enhance progression‑free survival
Comparison of combination therapy versus monotherapy to improve overall survival
Study of peri‑operative chemotherapy with immunotherapy to assess event‑free survival in resectable NSCLC

At Katholisches Klinikum Koblenz Montabaur gGmbH, six investigators are running three clinical trials aimed at testing innovative treatment strategies and advancing care for patients with lung cancer.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location

Rudolf-Virchow-Strasse 7, Rauental56073 KoblenzGermany

Open in maps ↗

Recruiting now: 3 trials
Conditions studied: 12

More sites in Koblenz Germany

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Quick filters

9 clinical trials

Non-small cell lung cancer stage III

Recruiting

Registered drugNo placebo

Pumitamig Versus Durvalumab in Patients With Unresectable Stage III Non-Small Cell Lung Cancer Without Progression After Chemoradiation

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Durvalumab
Sponsor:Bristol-Myers Squibb Services Unlimited Company

Contact Research Centre

Non-small cell lung cancer stage IIIA+2

Recruiting

Registered drugNo placebo

Testing MK-2870 with pembrolizumab compared to pembrolizumab alone after surgery in patients with non-small cell lung cancer who did not respond fully to treatment

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Study of Rilvegostomig or Pembrolizumab for First-line Treatment in Patients with PD-L1-high Metastatic Non-small Cell Lung Cancer

Recruiting

Registered drugNo placebo

Study of Rilvegostomig or Pembrolizumab for First-line Treatment in Patients with PD-L1-high Metastatic Non-small Cell Lung Cancer

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Infliximab
Sponsor:AstraZeneca AB

Contact Research Centre

Breast cancer+4

Not recruiting

Registered drugNo placebo

Study Comparing Ribociclib and Endocrine Therapy to Chemotherapy for Patients with Intermediate-Risk HR+/HER2- Early Breast Cancer

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Ribociclib
Sponsor:WSG Women's Cancer Study Group GmbH

Contact Research Centre

Lung neoplasm malignant

Not recruiting

Registered drug

Study on Durvalumab and Domvanalimab for Patients with Stage III Unresectable Non-Small Cell Lung Cancer After Chemoradiation Therapy

Registered drug

Germany

Participants:18–64 years · 65+ years
Substances:Domvanalimab
Sponsor:AstraZeneca AB

Contact Research Centre

Non-small cell lung cancer

Not recruiting

Registered drugNo placebo

Study on Atezolizumab for Patients with Non-Small Cell Lung Cancer After Chemotherapy

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Atezolizumab
Sponsor:F. Hoffmann-La Roche AG

Contact Research Centre

Non-small cell lung cancer

Not recruiting

Registered drugNo placebo

Study of Datopotamab Deruxtecan, Durvalumab, and Carboplatin for Advanced Non-Small Cell Lung Cancer in Patients Without Actionable Genomic Alterations

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:AstraZeneca AB

Contact Research Centre

Non-small cell lung cancer

Not recruiting

Registered drug

Study of Pembrolizumab with Chemotherapy for Patients with Resectable Stage II, IIIA, and IIIB Non-Small Cell Lung Cancer

Registered drug

Germany

Participants:18–64 years · 65+ years
Substances:Cisplatin
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Non-small cell lung cancer metastatic

Not recruiting

Registered drugNo placebo

Study Comparing Pembrolizumab Alone and with Sacituzumab Govitecan for Patients with Metastatic Non-Small Cell Lung Cancer with High PD-L1 Levels

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Pembrolizumab
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Is this your site?

Join our network of research sites

Get verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.

See the offer for sites